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Objectives: The prognosis for patients with large-cell neuroendocrine carcinoma is generally very poor. In this
study, we describe the clinical features of recurrent tumors of large-cell neuroendocrine carcinoma and discuss
the role of adjuvant chemotherapy and management of recurrence in patients with large-cell neuroendocrine
carcinoma.
Methods:We retrospectively analyzed clinical data from 79 patients and evaluated the prognosis of patients with
platinum-based adjuvant chemotherapy, recurrence patterns, patient response to chemotherapy or radiation ther-
apy, and prognosis in patients who experienced relapse.
Results:Of 72 patients, 36 had confirmed recurrent tumors upon follow-up examinations. Of those with recurrent
tumors, 33 patients (91.7%) had their first recurrent tumors within 3 years. Patients who underwent platinum-
based adjuvant chemotherapy had a significantly lower rate of tumor recurrence and a higher rate of disease-
free survival than those who had non–platinum-based adjuvant chemotherapy or no adjuvant chemotherapy.
Multivariate analyses revealed that platinum-based adjuvant chemotherapy, pathologic stage, and the presence
of second cancer are independent prognostic factors. Three patients with limited resection of the primary tumor
had poor prognosis with recurrence. Postoperatively, 11 of the 36 patients without recurrence (30.6%) had meta-
chronous second primary cancers, of which 4 patients had more than 1 site.
Conclusions: Patients with large-cell neuroendocrine carcinoma had frequent recurrence following resection of
the primary tumor, and those without recurrence often developed metachronous second primary cancers. Plati-
num-based adjuvant chemotherapy after surgery may be useful for preventing recurrence in patients with
large-cell neuroendocrine carcinoma.It has been found that the biologic behavior of large-cell neu-
roendocrine carcinoma (LCNEC) tumors resembles that of
small-cell lung carcinomas, that LCNECs show features of
high-grade neuroendocrine tumors, and that LCNECs are
aggressive tumors and patients with LCNEC have very
poor prognoses.1-9 Based on the following studies, the effi-
cacy of adjuvant chemotherapy should be examined for pa-
tients with LCNEC.10-12 Iyoda and colleagues12 performed
a prospective study beginning in 2000 on the use of adjuvant
chemotherapy for patients with LCNEC. They selected cis-
platin þ etoposide for their chemotherapeutic regimen,
which is similar to that used for small-cell lung carcinoma
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are very similar. Their results showed good prognosis for pa-
tients with adjuvant chemotherapy based on cisplatin þ
etoposide after complete surgical resection. Rossi and col-
leagues13 also reported that adjuvant chemotherapy based
on cisplatin þ etoposide was effective for patients with
LCNEC in a retrospective study. Thus, adjuvant chemother-
apy following complete resection of LCNEC tumors appears
promising for improving prognosis. However, little is
known regarding recurrence of LCNEC tumors. Identifica-
tion of frequent sites of recurrence and an understanding
of the role of adjuvant chemotherapy are necessary for plan-
ning treatment of patients with LCNEC who have had sur-
gery as an initial treatment. In this study, we describe the
clinical features of recurrent tumors of LCNEC and discuss
the role of adjuvant chemotherapy and management of
recurrence in patients with LCNEC.
PATIENTS AND METHODS
We retrospectively analyzed clinical data from 79 patients with primary
lung carcinoma diagnosed as LCNEC who underwent treatment at Chiba
University Hospital. In resected specimens after surgery, LCNEC was diag-
nosed if there were both evidence of neuroendocrine differentiation detected
by immunohistochemistry or electron microscopy and the following neuro-
endocrine morphologic features: (1) neuroendocrine morphology such asrgery c August 2009
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CT ¼ computed tomography
LCNEC ¼ large-cell neuroendocrine carcinoma
organoid nesting, palisading, rosettes, and trabeculae; (2) a high mitotic rate
of at least 11 per 2 mm2 (10 high-power fields); (3) necrosis (often large
zone); (4) cytologic features of a non–small cell carcinoma including large
cell size, low nuclear-to-cytoplasm volume ratio, vesicular or fine chroma-
tin, and/or frequent nucleoli. Immunohistochemical staining was done using
a polyclonal anti-chromogranin A antibody (Nichirei Corporation, Tokyo,
Japan), a monoclonal anti-synaptophysin antibody (DAKO, Glostrup, Den-
mark), and an anti-neural cell adhesion molecule (NCAM) antibody
(Zymed, South San Francisco, Calif). Neuroendocrine differentiation was
identified by positive immunohistochemical staining for chromogranin
A, synaptophysin, or NCAM.1,12
The following parameters were investigated from the medical records:
patient gender, age, smoking index, tumor size, tumor location, surgical pro-
cedure, pathologic TNM stage, adjuvant chemotherapy, time of recurrence,
site of recurrence, response to treatment, and patient outcome.
Treatments and Evaluation
We evaluated the response of LCNEC recurrent tumors based on Re-
sponse Evaluation Criteria in Solid Tumors Guidelines.14 We performed
routine follow-ups of patients with LCNEC 3 or 4 times per year, checking
symptoms and chest roentgenography. We also performed chest computed
tomography (CT) at least one time per year. If abnormal findings were ob-
served, we used CT to evaluate the hilar-mediastinal and extrathoracic
lymph nodes, the lung field, and the abdomen, and we used magnetic reso-
nance imaging or CT to evaluate brain lesions. Bone scintigraphy was usedThe Journal of Thoracic and Cto evaluate bone metastases. In some patients, we used positron emission
tomography scans to detect postoperative distant metastases. If recurrent
tumors were suspected, other sites were also examined.
Because this was a retrospective study, the treatment was not unified,
especially treatment of recurrent tumors. However, a prospective study on
the use of adjuvant chemotherapy was begun in 2000, and patients with
LCNEC have been evaluated on the efficacy of adjuvant chemotherapy
using cisplatin þ etoposide following surgery, except for those patients
without inclusion criteria.12
The Institutional Review Board of Chiba University Hospital approved
protocols and procedures.
Statistical Analysis
Fisher exact test was used to compare binomial proportions. The Wil-
coxon test and c2 test were used to assess differences in treatment. Survival
time was calculated from the date of surgery until the time of recurrence or
death or date of last follow-up and was evaluated using the method of
Kaplan and Meier. Curves obtained were compared using the log-rank
test. The prognostic impact of the following clinical variables was investi-
gated using Cox proportional hazards multivariable regression model and
propensity score analysis: platinum-based adjuvant chemotherapy ( vs
þ), gender (male vs female), age (<65 years vs65 years), pathologic stage
(Ia or Ib vs IIa, IIb, IIIa, IIIb, or IV). Surgery (standard operation vs limited
resection), postoperative complication (vsþ), and second cancer (vsþ).
In propensity score analysis, we made a propensity score for the factor of
platinum-based adjuvant chemotherapy, selected matching cases for pro-
pensity score, and compared the prognosis of patients with platinum-based
adjuvant chemotherapy with the prognosis of patients without those.
RESULTS
All patients had surgical resections of their primary tu-
mors, which were then histologically determined to beG
T
STABLE 1. Characteristics of 72 informative patients with large-cell neuroendocrine carcinoma between group with platinum-based adjuvant
chemotherapy and group without
Adjuvant chemotherapy
Factor Category þ  P value
Number 30 (100.0%) 42 (100.0%)
Age (y) Mean 63.2 65.8 .326 (Wilcoxon)
Standard deviation 9.6 7.7
Gender Male 30 (100.0%) 36 (85.7%) .037 (Fisher)
Female 0 (0.0%) 6 (14.3%)
Pathologic stage Ia 8 (26.7%) 12 (28.6%) .898 (Wilcoxon)
Ib 6 (20.0%) 9 (21.4%)
IIa 0 (0.0%) 1 (2.4%)
IIb 4 (13.3%) 3 (7.1%)
IIIa 7 (23.3%) 9 (21.4%)
IIIb 4 (13.3%) 8 (19.0%)
IV 1 (3.3%) 0 (0.0%)
Surgery Pneumonectomy 1 (3.3%) 5 (11.9%) .736 (Wilcoxon)
Bilobectomy 3 (10.0%) 1 (2.4%)
Lobectomy 25 (83.3%) 32 (76.2%)
Segmentectomy 0 (0.0%) 1 (2.4%)
Wedge resection 1 (3.3%) 3 (7.1%)
Postoperative complication  26 (86.7%) 37 (88.1%) >.999 (Fisher)
þ 4 (13.3%) 5 (11.9%)
Second cancer  26 (86.7%) 33 (78.6%) .537 (Fisher)
þ 4 (13.3%) 9 (21.4%)
Postoperative recurrence  20 (66.7%) 16 (38.1%) .017 (c2)
þ 10 (33.3%) 26 (61.9%)ardiovascular Surgery c Volume 138, Number 2 447
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SLCNEC. Of 79 cases, we were unable to evaluate 7 cases
due to a lack of information regarding recurrent tumors.
Characteristics of the 72 patients examined in this study
are shown in Table 1. Of the 72 patients with information
on recurrence, 36 did not have recurrent tumors, and in the
other 36, recurrent tumors were detected during follow-up
examination after surgery.
The 5-year disease-free survival for the 72 patients was
42.7%. Of the 36 patients with recurrent tumors, 23
(63.9%) had their first recurrent tumor within 1 year follow-
ing the operation, and 33 (91.7%) had tumors within 3 years
(Table 2). The 5-year overall survival rate for patients with
recurrent tumors was 12.5%, which was significantly worse
than the rate of patientswithout recurrence (88.7%;P<.0001).
Sites of recurrence included hilar, mediastinal, or supra-
clavicular lymph nodes in 18 patients, lungs in 12 patients,
brain in 11 patients, bone in 8 patients, and liver in 7 patients.
Pleural dissemination was observed in 2 patients. One recur-
rence each was detected in the adrenal gland, skin, local re-
currence, retroperitoneal lymph node, and axillary lymph
node (Table 3). Nineteen patients had recurrent tumors
with more than 1 site.
We examined the relationship between postoperative ad-
juvant chemotherapy and tumor recurrence (Table 1). The
group that received platinum-based adjuvant chemotherapy
had a significantly lower rate of tumor recurrence than the
groups with either non–platinum-based adjuvant chemother-
TABLE 2. Duration from date of surgery until time of tumor
recurrence
Duration (mo) Number of cases
3 4
4–6 6
7–12 13
13–24 6
25–36 4
37 3448 The Journal of Thoracic and Cardiovascular Suapy or no adjuvant chemotherapy (P ¼ .0168). The 5-year
disease-free survival rates of patients with platinum-based
adjuvant chemotherapy and patients without were 58.9%
and 33.0%, respectively, and the disease-free survival rates
showed that patients with platinum-based adjuvant chemo-
therapy had significantly better prognoses than patients
without (P ¼ .0444, Figure 1). Multivariate analyses re-
vealed that platinum-based adjuvant chemotherapy, patho-
logic stage, and the presence of second cancer are
independent prognostic factors (Table 4). Table 5 shows 2
groups divided by propensity score. There were no signifi-
cant differences on prognosis in propensity score analyses
between the group with platinum-based adjuvant chemo-
therapy and the group without (P ¼ .14, Figure 2). Five pa-
tients had limited surgery for LCNEC, and of these, 4
patients had poor prognosis (3 with recurrence, 1 without re-
currence) and only 1 patient with wedge resection survived
without recurrence (Table 6).
Postoperatively, of the 36 patients without recurrence, 11
(30.6%) patients hadmetachronous second primary cancers,
of which 4 patients had recurrence at more than 1 site (Table
7). Of the 11 patients, only 4 patients underwent postopera-
tive adjuvant chemotherapy. Four patients died due to the
second primary cancers.
We examined the treatment and response to platinum-
based chemotherapy or radiation therapy for hilar, mediasti-
nal, or supraclavicular lymph node recurrence. In 15 of 18
patients with hilar, mediastinal, or supraclavicular lymph
node recurrence, 7 patients (46.7%) had either complete
or partial response to treatment (Table 3). One patient who
had platinum-based chemotherapy (carboplatinþetoposide)
and 2 patients who had radiation therapy (42 Gy, 66 Gy) had
a complete response, while 4 patients who had radiation
therapy (48.5 Gy, 60 Gy, 60 Gy, 66 Gy) showed a partial
response, and 1 who had radiation therapy had progressive
disease (Table 8). All of the patients having non–platinum-
based chemotherapy had progressive disease.TABLE 3. Sites of recurrent tumors and responses to treatment
Evaluated
CR (n ¼ 4) PR (n ¼ 8) SD (n ¼ 2) PD (n ¼ 28) Not evaluated (n ¼ 22) Total (n ¼ 64)
Hilar, mediastinal, or
supraclavicular lymph node
3 4 0 8 3 18
Lung 1 1 0 6 4 12
Brain 0 2 2 6 2 12
Bone 0 0 0 3 5 8
Liver 0 0 0 1 6 7
Dissemination 0 1 0 1 0 2
Adrenal gland 0 0 0 1 0 1
Skin 0 0 0 0 1 (ope) 1
Local 0 0 0 1 0 1
Retroperitoneal lymph node 0 0 0 1 0 1
Axillary lymph node 0 0 0 0 1 (ope) 1
CR, Complete response; ope, operation; PD, progressive disease; PR, partial response; SD, stable disease.rgery c August 2009
Iyoda et al General Thoracic SurgeryFIGURE 1. Disease-free survival curves of patients with large-cell neuroendocrine carcinoma with and without platinum-based adjuvant chemotherapy.G
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SIn 8 of 12 patients with lung metastases (Table 3), only 2
patients showed any response to treatment. One patient us-
ing 60-Gy radiation therapy with carboplatin had a complete
response, 1 patient using 60-Gy radiation therapy had a par-
tial response, and 6 patients overall showed progressive dis-
ease, of which 2 patients received non–platinum-based
chemotherapy (Table 8).
In 11 patients, there were 12 instances of brain metastases
(Table 3). Of 10 informative cases, only 2 patients had a par-The Journal of Thoracic andtial response: 1 patient with radiation therapy with 30 Gy and
another with g-knife of 20 Gy (Table 8).
DISCUSSION
Patients with LCNEC generally have poor prognosis. Iyoda
and colleagues3 reported a 35.5% 5-year survival rate and
a 27.4% 5-year disease-free survival rate. Other studies have
also reported poor prognosis for patients with LCNEC, with
5-year survival rates ranging from 15% to 57%.2,4,13,15-18TABLE 4. The prognostic impact using Cox proportional hazards multivariable regression model
Univariate Multivariate
Factor Category n 5-year DFS predicted value from Kaplan-Meier (%) HR P value HR P value
Adjuvant chemotherapy  42 32.97 1.000 1.000
þ 30 58.93 0.500 .042 0.350 .005
Age (y) <65 26 55.90 1.000 1.000
65 46 35.80 1.954 .050 1.951 .078
Gender Male 66 44.06 1.000 1.000
Female 6 33.33 0.877 .805 0.365 .086
Stage Ia/Ib 35 57.46 1.000 1.000
IIa/IIb/IIIa/IIIb/IV 37 29.73 2.273 .011 2.176 .025
Surgery Standard 67 45.00 1.000 1.000
Limited 5 20.00 1.530 .421 0.823 .732
Postoperative complication  63 44.68 1.000 1.000
þ 9 33.33 1.701 .203 1.067 .886
Second cancer  59 35.55 1.000 1.000
þ 13 76.15 0.388 .048 0.242 .008
DFS, Disease-free survival; HR, hazard ratio.Cardiovascular Surgery c Volume 138, Number 2 449
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STABLE 5. Patient characteristics using propensity score analyses
Adjuvant chemotherapy
Factor Category þ  P value
Number 26 (100.0%) 26 (100.0%)
Age (y) Mean 64.0 64.2 .715 (Wilcoxon)
Standard deviation 9.9 8.0
Gender Male 26 (100.0%) 26 (100.0%) >.999 (Fisher)
Female 0 (0.0%) 0 (0.0%)
Pathologic stage Ia 8 (30.8%) 9 (34.6%) .807 (Wilcoxon)
Ib 6 (23.1%) 6 (23.1%)
IIa 0 (0.0%) 0 (0.0%)
IIb 3 (11.5%) 3 (11.5%)
IIIa 7 (26.9%) 5 (19.2%)
IIIb 1 (3.8%) 3 (11.5%)
IV 1 (3.8%) 0 (0.0%)
Surgery Pneumonectomy 1 (3.8%) 5 (19.2%) .619 (Wilcoxon)
Bilobectomy 3 (11.5%) 0 (0.0%)
Lobectomy 21 (80.8%) 20 (76.9%)
Segmentectomy 0 (0.0%) 0 (0.0%)
Wedge resection 1 (3.8%) 1 (3.8%)
Postoperative complication  22 (84.6%) 24 (92.3%) .668 (Fisher)
þ 4 (15.4%) 2 (7.7%)
Second cancer  22 (84.6%) 21 (80.8%) >.999 (Fisher)
þ 4 (15.4%) 5 (19.2%)Even those patients with LCNEC at pathologic stage I show
poor prognosis, with 5-year survival rates of 27% to 67%.
Therefore, surgery alone may not be sufficient for treating
LCNEC. In 2001, Iyoda and colleauges10 revealed that adju-
vant chemotherapy was effective for treating patients with
LCNEC.10 Rossi and associates13 in 2005 and Iyoda and
colleagues12 in 2006 showed that patients receiving adjuvant
chemotherapy, especially cisplatinþetoposide, hadgood prog-nosis after complete surgical resection and that adjuvant che-
motherapy was promising for patients with LCNEC.
In this study, we determined that platinum-based adjuvant
chemotherapy for LCNEC patients following surgery was
significant in preventing recurrence. Although many pa-
tients with advanced-stage LCNEC were included in our
study, we had comparatively better prognoses than other re-
ports, likely due to the inclusion of patients with LCNECFIGURE 2. Disease-free survival curves of matching cases for propensity score analyses.
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Age (y) Gender Surgical procedure Tumor size (cm) N, M Status
75 Female Wedge resection 2.0 N0M0 Deceased (46 mo)
75 Male Wedge resection 1.7 N0M0 Deceased (2 mo)
68 Male Wedge resection 2.0 N0M0 Alive (46 mo)
69 Male Segmentectomy 1.4 N0M0 Deceased (28 mo)
67 Male Wedge resection 4.4 N0M0 Deceased (11 mo)
N, Lymph node metastasis; M, distant metastasis.G
T
Streated with platinum-based adjuvant chemotherapy. More-
over, multivariate analyses revealed that platinum-based ad-
juvant chemotherapy was a significant prognostic factor in
patients with LCNEC, although propensity score analyses
could not show those. In this study, platinum-based adjuvant
chemotherapy was promising for patients with LCNEC.
Previous reports have found that LCNEC tumors show
good response to chemotherapy.11 However, there have
been few reports on treatment for patients with LCNEC
and limited information on sites of recurrent tumors. More-
over, many clinicians could not resolve the kinds of treat-
ment performed for patients with recurrent tumors of
LCNEC, and the treatments were not unified. Therefore,
a limitation of this study was due to results conducted
from this retrospective analysis. However, we were able to
glean much information regarding the frequent sites of re-
current tumors and responses to actual treatment methods
used. Many patients with recurrent tumors of LCNEC had
very poor prognosis, but other patients showed good re-
sponses to treatment, especially treatment with platinum-
based chemotherapy, radiation therapy, and the combination
of the 2. Thus platinum-based chemotherapy or radiation
TABLE 7. Postoperative second primary cancer in 36 patients without
recurrence
Age (y) Gender Postoperative second cancer Status
55 Male Gastric cancer Alive
56 Male Rectal cancer Alive
58 Male Gastric cancer Alive
66 Male Esophageal cancer,
pharyngeal cancer,
urinary bladder cancer
Alive
67 Male Lung cancer Died from
second cancer
70 Male Esophageal cancer Died from
second cancer
70 Male Pharyngeal cancer,
gastric cancer
Died from
second cancer
71 Male Gastric cancer,
lung cancer
Alive
72 Male Cholangiocarcinoma Alive
73 Male Vocal cord cancer,
esophageal cancer
Died from
second cancer
74 Male Lung cancer AliveThe Journal of Thoracic andtherapy appears promising as effective treatments for
LCNEC recurrent tumors.
In examining the follow-ups of LCNECpatients, we found
that most recurrent tumors occurred within 3 years after sur-
gery and that patients with LCNEC showed frequent brain
metastases. Metastatic brain tumors of LCNEC are not al-
ways responsive to treatment. Therefore, we should use brain
magnetic resonance imaging to carefully follow patients after
resection of LCNEC tumors. Gamma knife treatment is
useful for metastatic brain tumors,19 and in this study, of
2 patients treated by gamma knife, 1 patient had a partial
response. Treatment of brain metastases in patients with
LCNEC is very difficult, but gamma knife treatment may
be a useful strategy for metastatic brain tumors of LCNEC.
TABLE 8. Treatment and response for hilar, mediastinal, or
supraclavicular lymph node recurrence, lung metastases, and brain
metastases
Evaluated
CR PR SD PD Not evaluated Total
LN recurrence 3 4 0 8 3 18
PB chemotherapy 1 0 0 0 0 1
NPB chemotherapy 0 0 0 3 0 3
Radiation therapy 2 4 0 1 0 7
Chemoradiation 0 0 0 0 1 1
Conservative 0 0 0 4 1 5
Unknown 0 0 0 0 1 1
Lung metastases 1 1 0 6 4 12
PB chemotherapy 0 0 0 1 0 1
NPB chemotherapy 0 0 0 2 0 2
Radiation therapy 0 1 0 0 0 1
Chemoradiation 1 0 0 0 0 1
NKT therapy 0 0 0 1 0 1
Conservative 0 0 0 2 1 3
Unknown 0 0 0 0 3 3
Brain metastases 0 2 2 6 2 12
Radiation therapy 0 1 1 0 0 2
g-knife 0 1 1 0 1 3
Operationþ radiation therapy 0 0 0 3 0 3
Chemoradiation 0 0 0 1 0 1
Operation 0 0 0 1 0 1
Conservative 0 0 0 1 0 1
Unknown 0 0 0 0 1 1
LN, Lymph node; PB, platinum-based; NPB, non–platinum-based; CR, complete re-
sponse; PR, partial response; SD, stable disease; PD, progressive disease;NKT, natural
killer T cells.Cardiovascular Surgery c Volume 138, Number 2 451
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SNatural killer T cells show strong antitumor activity
against various malignant tumors both in vitro and in vivo,
producing a high level of cytokines. Treatment using natural
killer T cells appears promising as an effective method in
lung cancer patients.20 In this study, the use of natural killer
T cells was performed in only 1 patient with pulmonary me-
tastasis, and the treatment effectiveness was not able to be
determined.
Recently, some clinicians have performed limited resec-
tion rather than standard lobectomy for small non–small
cell lung cancers, especially adenocarcinoma.21 However,
our study showed that patients with limited resection of pri-
mary LCNEC tumors frequently experienced recurrence;
therefore, if possible, standard operation should be per-
formed, even with small LCNEC tumors.
Although it is important to check for LCNEC tumor recur-
rence, we must also be aware of new cancer lesions, includ-
ing those at other sites. Our results showed a high rate of
postoperative secondary cancers following surgery for
LCNEC tumors. The incidence of second primary digestive
cancer after resection of lung cancer has been reported as
1% to 2%.22 The number of patients successfully treated
for their initial non–small cell lung carcinoma and at risk
of developing a second non–small cell lung carcinoma has
been reported as approximately 1% to 2%.23,24 From this
point of view, our results revealed a very high rate for devel-
oping a second primary cancer in patients with LCNEC, in-
cluding 4 patients who had more than 1 tumor. As only 4 of
11 patients with a second primary cancer had adjuvant che-
motherapy, we cannot necessarily consider that the second
primary cancers were caused by adjuvant chemotherapy.25
Even if 36 of 72 patients did not show LCNEC tumor recur-
rences, 11 patients had a metachronous second primary can-
cer, and 4 of 11 patients died due to their second primary
cancer. Although LCNEC tumors show aggressive behavior
as a matter of course, this may be one reason that patients
with LCNEC have poor prognosis.
In conclusion, although it has been reported that
LCNEC patients have frequent recurrent tumors and
very poor prognoses, we determined that platinum-based
adjuvant chemotherapy after surgery significantly prevents
recurrence and that recurrent tumors may also be respon-
sive to platinum-based chemotherapy, radiation therapy,
or the combination of the 2. In addition, if possible, lim-
ited resection of LCNEC tumors should not be performed
due to the poor outcome. Frequent areas of recurrence in-
clude the thoracic lymph nodes, lung, brain, bone, and
liver, and it is important to look for recurrence within
the first 3 years after surgical resection, as well as evi-
dence of postoperative secondary cancers. The results of
this study are very important, not only to consider treat-
ment and follow-up methods of patients with LCNEC,
but also to understand the biologic behavior and develop-
ment of LCNEC.452 The Journal of Thoracic and Cardiovascular SuReferences
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